Cargando…

Faecal calprotectin concentration in children with coeliac disease

INTRODUCTION: It is still unknown whether faecal calprotectin elevation may be caused by active untreated coeliac disease (CD) itself or whether it indicates the coexistence of CD and another disease associated with gastrointestinal inflammation. AIM: To assess faecal calprotectin concentration (FCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Szaflarska-Popławska, Anna, Romańczuk, Bartosz, Parzęcka, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089857/
https://www.ncbi.nlm.nih.gov/pubmed/32215127
http://dx.doi.org/10.5114/pg.2020.93630
_version_ 1783509805577535488
author Szaflarska-Popławska, Anna
Romańczuk, Bartosz
Parzęcka, Monika
author_facet Szaflarska-Popławska, Anna
Romańczuk, Bartosz
Parzęcka, Monika
author_sort Szaflarska-Popławska, Anna
collection PubMed
description INTRODUCTION: It is still unknown whether faecal calprotectin elevation may be caused by active untreated coeliac disease (CD) itself or whether it indicates the coexistence of CD and another disease associated with gastrointestinal inflammation. AIM: To assess faecal calprotectin concentration (FCC) and its correlation with the clinical form and histopathological picture of the small intestine in children with CD. MATERIAL AND METHODS: Fifty-five children with newly recognised CD (mean age: 9.1 years) and 17 children with CD diagnosed at least year before and on a strict gluten-free diet (mean age: 12.3 years) were accepted for the study. Classical (n = 27), non-classical (n = 17), and asymptomatic form (n = 11) were distinguished in children with newly diagnosed CD based on the clinical picture. The histopathological small intestinal lesions were classified as Marsh 1 (n = 4), 3a (n = 5), 3b (n = 20), and 3c (n = 26). FCC was assessed using ELISA method with 50 µg/g as the upper limit of the normal. RESULTS: FCC was abnormal for 21 patients with newly diagnosed CD (38.2%) and for six patients from the treated group (35.3%). Mean FCC for the analysed group of patients was 91.7 ±144.8 µg/g, in the group with newly diagnosed CD – 100.9 ±154.4 µg/g, and in the treated group – 61.8 ±106.2 µg/g (Z = –1.333; p = 0.183). In the group of patients with recently diagnosed CD a statistically significant relationship was not observed for FCC and both clinical picture (χ(2) = 0.319, p = 0.852) and severity of small intestinal lesions according to the Marsh classification (rho = 0.136). CONCLUSIONS: Assessment of FCC seems to have no use as a marker for diagnostics and monitoring of CD irrespective of clinical form of the disease and severity of the inflammatory lesions within the small intestine.
format Online
Article
Text
id pubmed-7089857
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-70898572020-03-25 Faecal calprotectin concentration in children with coeliac disease Szaflarska-Popławska, Anna Romańczuk, Bartosz Parzęcka, Monika Prz Gastroenterol Original Paper INTRODUCTION: It is still unknown whether faecal calprotectin elevation may be caused by active untreated coeliac disease (CD) itself or whether it indicates the coexistence of CD and another disease associated with gastrointestinal inflammation. AIM: To assess faecal calprotectin concentration (FCC) and its correlation with the clinical form and histopathological picture of the small intestine in children with CD. MATERIAL AND METHODS: Fifty-five children with newly recognised CD (mean age: 9.1 years) and 17 children with CD diagnosed at least year before and on a strict gluten-free diet (mean age: 12.3 years) were accepted for the study. Classical (n = 27), non-classical (n = 17), and asymptomatic form (n = 11) were distinguished in children with newly diagnosed CD based on the clinical picture. The histopathological small intestinal lesions were classified as Marsh 1 (n = 4), 3a (n = 5), 3b (n = 20), and 3c (n = 26). FCC was assessed using ELISA method with 50 µg/g as the upper limit of the normal. RESULTS: FCC was abnormal for 21 patients with newly diagnosed CD (38.2%) and for six patients from the treated group (35.3%). Mean FCC for the analysed group of patients was 91.7 ±144.8 µg/g, in the group with newly diagnosed CD – 100.9 ±154.4 µg/g, and in the treated group – 61.8 ±106.2 µg/g (Z = –1.333; p = 0.183). In the group of patients with recently diagnosed CD a statistically significant relationship was not observed for FCC and both clinical picture (χ(2) = 0.319, p = 0.852) and severity of small intestinal lesions according to the Marsh classification (rho = 0.136). CONCLUSIONS: Assessment of FCC seems to have no use as a marker for diagnostics and monitoring of CD irrespective of clinical form of the disease and severity of the inflammatory lesions within the small intestine. Termedia Publishing House 2020-03-19 2020 /pmc/articles/PMC7089857/ /pubmed/32215127 http://dx.doi.org/10.5114/pg.2020.93630 Text en Copyright © 2020 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Original Paper
Szaflarska-Popławska, Anna
Romańczuk, Bartosz
Parzęcka, Monika
Faecal calprotectin concentration in children with coeliac disease
title Faecal calprotectin concentration in children with coeliac disease
title_full Faecal calprotectin concentration in children with coeliac disease
title_fullStr Faecal calprotectin concentration in children with coeliac disease
title_full_unstemmed Faecal calprotectin concentration in children with coeliac disease
title_short Faecal calprotectin concentration in children with coeliac disease
title_sort faecal calprotectin concentration in children with coeliac disease
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089857/
https://www.ncbi.nlm.nih.gov/pubmed/32215127
http://dx.doi.org/10.5114/pg.2020.93630
work_keys_str_mv AT szaflarskapopławskaanna faecalcalprotectinconcentrationinchildrenwithcoeliacdisease
AT romanczukbartosz faecalcalprotectinconcentrationinchildrenwithcoeliacdisease
AT parzeckamonika faecalcalprotectinconcentrationinchildrenwithcoeliacdisease